MA48602A - Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha - Google Patents
Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alphaInfo
- Publication number
- MA48602A MA48602A MA048602A MA48602A MA48602A MA 48602 A MA48602 A MA 48602A MA 048602 A MA048602 A MA 048602A MA 48602 A MA48602 A MA 48602A MA 48602 A MA48602 A MA 48602A
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- phosphine oxide
- compounds substituted
- ifn alpha
- heteroaryl compounds
- Prior art date
Links
- -1 PHOSPHINE OXIDE AMIDE Chemical class 0.000 title 1
- 150000001875 compounds Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48602A true MA48602A (fr) | 2020-03-18 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048602A MA48602A (fr) | 2016-12-13 | 2017-12-12 | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (enExample) |
| EP (1) | EP3555111B1 (enExample) |
| JP (1) | JP7046092B2 (enExample) |
| KR (1) | KR102602558B1 (enExample) |
| CN (1) | CN110267964B (enExample) |
| AR (1) | AR110351A1 (enExample) |
| ES (1) | ES2907008T3 (enExample) |
| MA (1) | MA48602A (enExample) |
| TW (1) | TW201827423A (enExample) |
| WO (1) | WO2018111787A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274816B2 (en) | 2017-11-21 | 2023-12-01 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
| EP3768667B1 (en) * | 2018-03-22 | 2023-04-12 | Bristol-Myers Squibb Company | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| WO2021143498A1 (zh) * | 2020-01-19 | 2021-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| CN115160297B (zh) | 2020-12-22 | 2023-03-31 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| CN114805438A (zh) * | 2021-01-18 | 2022-07-29 | 正大天晴药业集团股份有限公司 | 含磷酰基的tyk2抑制剂化合物 |
| CN117083268B (zh) | 2021-03-16 | 2024-07-30 | 安锐生物医药科技(广州)有限公司 | 氨基杂芳基化合物和组合物 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270730A1 (en) | 2003-08-07 | 2006-11-30 | Andreas Katopodis | Histone deacetylase inhibitors as immunosuppressants |
| EP2300013B2 (en) * | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CN104125947A (zh) * | 2011-12-21 | 2014-10-29 | 生物区欧洲有限公司 | 杂环脲化合物 |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| AU2013341186B2 (en) | 2012-11-08 | 2017-03-30 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| AR093403A1 (es) | 2012-11-08 | 2015-06-03 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP2947460A1 (en) | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
-
2017
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active Active
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en not_active Ceased
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201827423A (zh) | 2018-08-01 |
| AR110351A1 (es) | 2019-03-20 |
| JP2020502268A (ja) | 2020-01-23 |
| US10294256B2 (en) | 2019-05-21 |
| CN110267964A (zh) | 2019-09-20 |
| KR102602558B1 (ko) | 2023-11-14 |
| CN110267964B (zh) | 2022-05-03 |
| US20180162889A1 (en) | 2018-06-14 |
| EP3555111A1 (en) | 2019-10-23 |
| ES2907008T3 (es) | 2022-04-21 |
| EP3555111B1 (en) | 2022-01-26 |
| JP7046092B2 (ja) | 2022-04-01 |
| KR20190091536A (ko) | 2019-08-06 |
| WO2018111787A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
| MA46453A (fr) | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha | |
| MA46620A (fr) | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha | |
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| IL256614B (en) | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated diseases | |
| EP3524603A4 (en) | FGFR4 INHIBITOR, PRODUCTION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | |
| BR112018007395A2 (pt) | 2,4-di-hidróxi-nicotinamidas como agonistas de apj | |
| EP3488361A4 (en) | RECORD VOTE SYSTEM | |
| BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| MX2017003359A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| EP3452407A4 (en) | METHOD AND USES FOR REMOVED TRIGGERED PROTEASE ACTIVITY MEASUREMENTS | |
| DK3240538T3 (da) | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| EP3602528A4 (en) | EXERCISE DEVICE WITH PISTON SIMULATION FOR PRE-FILLED SYRINGE | |
| EP3790461C0 (en) | SENSING CANNULA SYSTEMS | |
| EP3875542A4 (en) | SILICONE EMULSION COMPOSITION | |
| BR112018005208A2 (pt) | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana | |
| EP3528813A4 (en) | P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| MY192425A (en) | Polymorphs | |
| EP3551612A4 (en) | PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE | |
| EP3328368A4 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITION RELATING TO THE UBIQUITINATION PROTEASOM SYSTEM | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| EP3793550A4 (en) | Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same |